MRNA Moderna191.97-4.82 (-2.5%)
Outlook is neutral, with stock confined to a range of ±4%
Strategy has +53% ROI potential and 34% overvalued
Outlook is neutral, with stock confined to a range of ±9%
Strategy has +42% ROI potential and 56% overvalued
Outlook is neutral, requiring stock price to land between $250 and $278
Strategy has +86% ROI potential and 37% overvalued
Outlook is neutral, with stock confined to a channel of ±8%
Strategy has +64% ROI potential and 30% overvalued